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Debated Role of Ovarian Protection
With Gonadotropin-Releasing
Hormone Agonists During
Chemotherapy for Preservation of
Ovarian Function and Fertility in
Women With Cancer
TO THE EDITOR: In 2015, two large randomized controlled
trials (RCTs) in patients with breast cancer (ie, Prevention of Early
Menopause Study–Southwest Oncology Group [POEMS-SWOG]
S0230 and Prevention of Menopause Induced by Chemotherapy: A
Study in Early Breast Cancer Patients–Gruppo Italiano Mammella
6 [PROMISE-GIM6]) demonstrated improvement in both ovarian
function and fertility with gonadotropin-releasing hormone agonist (GnRHa) administration during chemotherapy.1,2 The consistent absolute and relative results support the reliability of these
ﬁndings (Table 1).1-3 The largest meta-analysis including all RCTs
in patients with breast cancer conﬁrmed a reduced risk of premature ovarian failure (POF; odds ratio [OR], 0.36; P , .001) and
an increased chance of achieving pregnancy (OR, 1.83; P 5.04) with
GnRHa during chemotherapy.4 On the basis of these ﬁndings,
current guidelines recommend use of GnRHa as a strategy to offer
patients with breast cancer who are interested in fertility and/or
ovarian function preservation.5
Demeestere et al3 have recently reported follow-up data from
their RCT investigating use of GnRHa during chemotherapy for
preservation of ovarian function and fertility in patients with
lymphoma. The authors concluded that after more than 5 years of
follow-up, GnRHa administration did not signiﬁcantly reduce
POF or increase pregnancy rate.3 However, several issues should
be considered in interpreting the results.
Although there is no standard deﬁnition of chemotherapyinduced POF, a composite end point using both clinical and
laboratory measures (eg, irregular periods or amenorrhea with
follicle-stimulating hormone [FSH] levels . 40 mIU/mL)6 lends
greater speciﬁcity. The role of anti-müllerian hormone (AMH),

C O R R E S P O N D E N C E

a marker of ovarian reserve commonly used in fertility clinics, is
controversial in predicting chemotherapy-induced gonadal damage and subsequent fertility loss.7 Demeestere et al3 relied only on
FSH or AMH levels, which might have increased false-positive
results that incorrectly identiﬁed patients as having POF who did
not in fact develop the event, as conﬁrmed by the observation of
ﬁve pregnancies in women with protocol-deﬁned POF.
Although pregnancy represents the best marker of fertility,
prevention of POF has other advantages in preserving quality of
life. None of the RCTs of ovarian protection with GnRHa required
interest in future pregnancy for eligibility, and only a minority
reported pregnancies. The POEMS-SWOG S0230 trial, the only
study to include pregnancy as a predeﬁned secondary end point,
showed a signiﬁcantly higher pregnancy rate with use of GnRHa.1,8
In the study by Demeestere et al,3 the use of the hormone
norethisterone acetate in both study arms during chemotherapy
may have diminished the observed protective effect of GnRHa.
Norethisterone acetate directly affects the hypothalamic-pituitary
axis, slowing gonadotropin-releasing hormone pulse frequency
and lowering gonadotropins9; this effect would only be seen in the
control arm, because the pituitary gonadotropin-releasing hormone receptors would be downregulated by the GnRHa in the
experimental arm.
Furthermore, 46% of patients had no information on the use of
hormonal contraceptives at the time of ovarian function assessment.3
Hormonal contraceptives can suppress FSH, which may have further
confounded the results, especially if use was unbalanced between the
two treatment arms.
According to the original analysis plan, 157 patients were
required; however, only 129 women were randomly assigned, with
84 patients (65%) completing 1 year of follow-up and included in
the primary analysis.10 Long-term analyses were not preplanned;
hence, the time points for ovarian function evaluation were not
prespeciﬁed or mandatory. Only 63 patients (49%) and 37 patients
(29%) had information on FSH and AMH, respectively.3 Although
reported as a negative study, the ORs for POF and pregnancy seen
in the trial by Demeestere et al3 are consistent with the protective
effect of GnRHa seen in other studies (Table 1) and may not have
achieved statistical signiﬁcance only because of lack of power.

Table 1. Main Results of the Largest Randomized Controlled Trials Investigating the Role of GnRHa During Chemotherapy in Preservation of Ovarian Function and
Fertility in Women With Cancer
Outcome

Demeestere et al3

POEMS-SWOG S02301

PROMISE-GIM62

Treatment-induced POF (CT 1 GnRHa v
CT alone), %
Patients with pregnancies (CT 1 GnRHa v
CT alone), %
Disease-free survival (CT 1 GnRHa v
CT alone), %

19 v 25 (OR, 0.72; P 5 .76)

8 v 22 (OR, 0.30; P 5 .04)

8.9 v 25.9 (OR, 0.28; P , .001)

53 v 43 (OR, 1.51; P 5 .47)

21 v 11 (OR, 2.45; P 5 .03)

5 v 2 (HR, 2.40; P 5 .20)

82 v 87.5 (NR)

89 v 78 (HR, 0.49; P 5 .04)

80.5 v 83.7 (HR, 1.17; P 5 .52)

Abbreviations: CT, chemotherapy; GnRHa, gonadotropin-releasing hormone agonist; HR, hazard ratio; NR, not reported; OR, odds ratio; POEMS-SWOG, Prevention of
Early Menopause Study–Southwest Oncology Group; POF, premature ovarian failure; PROMISE-GIM6, Prevention of Menopause Induced by Chemotherapy: A Study in
Early Breast Cancer Patients–Gruppo Italiano Mammella 6.
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Regarding the assessment of missing data, although characteristics between patients who did versus did not drop out were
similar,3 this is not relevant to the assessment of whether missing
data bias the treatment effect. It is more important to know whether
there was differential dropout between patients who did versus did
not drop out by arm using interaction tests. Finally, because their
study was not designed to test the equivalency of the two regimens,
the absence of a beneﬁcial effect with GnRHa cannot be claimed to
conﬁrm that GnRHa is not efﬁcient in preventing POF3; at best, the
study showed no evidence that GnRHa reduced the incidence of POF.
Although the study by Demeestere et al3 was unable to demonstrate ovarian protection with GnRHa during chemotherapy in
patients with lymphoma, this was an underpowered and exploratory
analysis of a study in which both control and experimental arm
patients received hormonal treatment and in which the end point
was ﬂawed. Hence, these results should be considered as exploratory
and do not refute ﬁndings from well-designed large RCTs on this
topic.
Although embryo or oocyte cryopreservation is the ﬁrst choice
for fertility preservation, GnRHa during chemotherapy remains
an option for women interested in preserving ovarian function and
fertility.
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